Pharmstandard nabs Russia’s Biocad, with a little oligarch aid

Carly Helfand

Last year, multinational drugmakers had their eyes on Russian biosimilars developer . But now, it's the country's own lead pharma company that will grab the St. Petersburg-based company.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS